Evidence map›Paper›PMID 38583835›Full record

ArticleInternational journal of biological macromolecules2024

Structural characterization of lytic transglycosylase MltD of Pseudomonas aeruginosa, a target for the natural product bulgecin A.

Vega Miguel-Ruano, Rhona Feltzer, María T Batuecas, Balajee Ramachandran, Amr M El-Araby, Luis F Avila-Cobian, Stefania De Benedetti, Shahriar Mobashery, Juan A Hermoso

Open access · hybridAbstract read
In one paragraph

Article in International journal of biological macromolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. A Concise Route to Orthogonally Protected Bulgecinine.The Journal of organic chemistry · 2026
    Article
  2. Bacterial peptidoglycan as a living polymer.Current opinion in chemical biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Vega Miguel-RuanoDepartment of Crystallography and Structural Biology, Instituto de Química-Física "Blas Cabrera", Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Rhona FeltzerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
María T BatuecasDepartment of Crystallography and Structural Biology, Instituto de Química-Física "Blas Cabrera", Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Balajee RamachandranDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Amr M El-ArabyDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Luis F Avila-CobianDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Stefania De BenedettiDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Shahriar MobasheryDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA. Electronic address: mobashery@nd.edu.
Juan A HermosoDepartment of Crystallography and Structural Biology, Instituto de Química-Física "Blas Cabrera", Consejo Superior de Investigaciones Científicas, Madrid, Spain. Electronic address: xjuan@iqf.csic.es.
University of Notre Dame · USConsejo Superior de Investigaciones Científicas · ES

Funding

Bulgecin Template for Potentiation of beta-Lactam AntibioticsR01AI148217 · NIAID · UNIVERSITY OF NOTRE DAME · PI MOBASHERY, SHAHRIAR · 2020 to 2024
$3.0M
Chemistry-Biochemistry-Biology Interface (CBBI) Program at Notre DameT32GM145773 · NIGMS · UNIVERSITY OF NOTRE DAME · PI Christian Corey Melander · 2022 to 2026
$1.5M
NIAID NIH HHS R01 AI148217NIGMS NIH HHS T32 GM145773
6 · The paper itself

Abstract

Natural product bulgecin A potentiates the activity of β-lactam antibiotics by inhibition of three lytic transglycosylases in Pseudomonas aeruginosa, of which MltD is one. MltD exhibits both endolytic and exolytic reactions in the turnover of the cell-wall peptidoglycan and tolerates the presence or absence of stem peptides in its substrates. The present study reveals structural features of the multimodular MltD, presenting a catalytic module and four cell-wall-binding LysM modules that account for these attributes. Three X-ray structures are reported herein for MltD that disclose one unpredicted LysM module tightly attached to the catalytic domain, whereas the other LysM modules are mobile, and connected to the catalytic domain through long flexible linkers. The formation of crystals depended on the presence of bulgecin A. The expansive active-site cleft is highlighted by the insertion of a helical region, a hallmark of the family 1D of lytic transglycosylases, which was mapped out in a ternary complex of MltD:bulgecinA:chitotetraose, revealing at the minimum the presence of eight subsites (from -4 to +4, with the seat of reaction at subsites -1 and + 1) for binding of sugars of the substrate for the endolytic reaction. The mechanism of the exolytic reaction is revealed in one of the structures, showing how the substrate's terminal anhydro-NAM moiety could be sequestered at subsite +2. Our results provide the structural insight for both the endolytic and exolytic activities of MltD during cell-wall-turnover events.

Indexed as

Catalytic DomainPseudomonas aeruginosaBacterial ProteinsBiological ProductsCell WallCrystallography, X-RayGlycosyltransferasesModels, MolecularSubstrate SpecificityBacterial ProteinsBiological ProductsGlycosyltransferasesBulgecin ALytic TransglycosylasePeptidoglycan recycling

Identifiers

PMID38583835
PMCPMC11327851
OpenAlexW4393971385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.